TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17435611
Drug: Iron polymaltose
Normalized name: iron polymaltose
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron polymaltose complex (IPC) (100 mg elemental iron)
Study: 15349137
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug treatment (baseline)
Study: 11332584
Drug: 50microg/day of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50microg/day of transdermal 17beta‐estradiol
Study: 9434661
Drug: Zinc (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (25 mg as zinc sulfate)
Study: 9434661
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A and Zinc (800 micrograms retinol palmitate and 25 mg as zinc sulfate)
Study: 7859694
Drug: Sorbitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (2 x 15 g)
Study: 7859694
Drug: Maltitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltitol (2 x 15 g)
Study: 7859694
Drug: Isomalt (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomalt (2 x 15 g)
Study: 7859694
Drug: Sorbitol (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (5, 10, or 20 g)
Study: 7859694
Drug: Isomalt (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomalt (5, 10, or 20 g)
Study: 7859694
Drug: Polyols (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyols (2 x 15 g intake)
Study: 2913680
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 vaginal tablets (0.5 mg) intravaginally every 6 hours
Study: 19295201
Drug: Urokinase (UK)
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urokinase (UK) administered intraventricularly every 12 hours until clinical response permitted EVD removal
Study: 19295201
Drug: Placebo (Pcb)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Pcb) administered intraventricularly every 12 hours until clinical response permitted EVD removal
Study: 15087045
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg cabergoline
Study: 15087045
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg cabergoline
Study: 3758244
Drug: Dextromethorphan-salbutamol combination
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan-salbutamol combination
Study: 12575602
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (megestrol acetate and Chinese medicine)
Study: 31405927
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of the D2 antagonist haloperidol
Study: 28927869
Drug: initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: initial combination therapy including prednisone
Study: 28927869
Drug: sequential DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential DMARD monotherapy
Study: 21415052
Drug: step-up combination
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: step-up combination therapy
Study: 25283471
Drug: Oral lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral lenalidomide 10 mg once daily
Study: 15659723
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus esomeprazole (80 mg aspirin daily + 20 mg esomeprazole twice daily)
Study: 7485927
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 3 g/day for 5 days
Study: 31103018
Drug: Oxytocin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (40 IU via nasal spray)
Study: 23937007
Drug: Hearing aids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hearing aids combined with psychological counseling therapy
Study: 23937007
Drug: Counseling therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling therapy only
Study: 15167120
Drug: 131I thyroid
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I thyroid doses
Study: 11848001
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate orally the evening before, clear liquid the day of the exam, and two Dulcolax suppositories the day of the exam
Study: 9204088
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel + Benzoyl peroxide
Study: 9204088
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel + Clindamycin phosphate
Study: 9204088
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel + Erythromycin
Study: 8894261
Drug: Atenolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50-100 mg/day)
Study: 28734853
Drug: D25 (dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D25 (dexmedetomidine 25 μg kg−1)
Study: 28734853
Drug: D25M300 (dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D25M300 (dexmedetomidine 25 μg kg−1 + MK-467 300 μg kg−1)
Study: 28734853
Drug: D25M600 (dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D25M600 (dexmedetomidine 25 μg kg−1 + MK-467 600 μg kg−1)
Study: 28734853
Drug: D25M1200 (dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D25M1200 (dexmedetomidine 25 μg kg−1 + MK-467 1200 μg kg−1)
Study: 28734853
Drug: M600 (MK-467
Approvals — FDA: no, EMA: no, PMDA: no
Description: M600 (MK-467 600 μg kg−1)
Study: 28734853
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments with dexmedetomidine
Study: 19506498
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (2 microg/kg)
Study: 16484572
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (AGE) administered for 6 months
Study: 16484572
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 6 months
Study: 10386195
Drug: Ketoconazole (400‐800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400‐800 mg/d p.o.)
Study: 1520082
Drug: Threonine at
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Threonine at a total daily dose of 7.5 g
Study: 6873148
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg at 20 h
Study: 6873148
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg at 8 h
Study: 6873148
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg at 12 h
Study: 17151158
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Study: 26075840
Drug: Perphenazine (first-generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (first-generation antipsychotic)
Study: 10543928
Drug: ramipril 1.25
Normalized name: ramipril 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 1.25 mg/day
Study: 6392223
Drug: AT1727 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AT1727 treatment side effects
Study: 11898235
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise during chemotherapy
Study: 23113947
Drug: Pyronaridine-artesunate granules
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pyronaridine-artesunate granules (60/20 mg) once daily for three days
Study: 23113947
Drug: Artemether-lumefantrine crushed
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine crushed tablets (20/120 mg) twice daily for three days
Study: 19648772
Drug: Domperidone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (0.3 mg/kg/8 h p.o. for at least 2 days)
Study: 18348296
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy after primary surgery
Study: 12509376
Drug: Pharmacists consulting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists consulting to family physicians for medication optimization
Study: 12509376
Drug: Medication use,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use, health care utilization, and general health
Study: 7532157
Drug: Intra-arterial hepatic
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial hepatic route (i.a.h.) administration of Cisplatin (CDDP)
Study: 7532157
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of Cisplatin (CDDP)
Study: 1821700
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of milnacipran (300 mg daily for 2 weeks, then 150 mg daily for 2 weeks)
Study: 1821700
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of milnacipran (200 mg daily for 4 weeks)
Study: 1821700
Drug: Fluvoxamine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (200 mg daily for 4 weeks)
Study: 27140216
Drug: Midazolam sequential
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam sequential with dexmedetomidine (loading dose of midazolam at 0.3-3 mg/kg·h for 24 h before extubation, followed by dexmedetomidine infusion at 0.2-1 μg/kg·h until extubation)
Study: 27140216
Drug: Midazolam (0.3-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.3-3 mg/kg·h until extubation)
Study: 27140216
Drug: Midazolam sequential
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam sequential with dexmedetomidine
Study: 24815795
Drug: Sildenafil (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (titrated to 80 mg, three times daily, as tolerated)
Study: 22348451
Drug: Low-dose melatonin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose melatonin (0.4mg)
Study: 22348451
Drug: High-dose melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melatonin (4.0mg)
Study: 18822087
Drug: Apomorphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine infusion
Study: 11357167
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (IL-1ra) 150 mg/d
Study: 11357167
Drug: IL-1ra 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1ra 1.0 mg/kg/d
Study: 11357167
Drug: IL-1ra 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1ra 2.0 mg/kg/d
Study: 9580575
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg LAAM
Study: 9580575
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg LAAM
Study: 8111576
Drug: HCl infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCl infusion (patients)
Study: 23686001
Drug: Panretinal photocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panretinal photocoagulation (PRP) associated with intravitreal bevacizumab (IVB) injections
Study: 20946162
Drug: Early rehabilitation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rehabilitation (sildenafil citrate twice weekly starting at 2 months postoperatively)
Study: 20946162
Drug: Late rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late rehabilitation (sildenafil citrate twice weekly starting at 6 months postoperatively)
Study: 11419823
Drug: Standard U.S.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard U.S. 13C‐urea breath test (125 mg of 13C‐urea, pudding test meal, breath sample taken 30 min after ingestion)
Study: 11419823
Drug: Simplified UBT‐Lite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified UBT‐Lite (75 mg of 13C‐urea, 2.5-g citric acid test meal, breath sample taken 15 min after ingestion)
Study: 12267108
Drug: ML Cu250
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML Cu250
Study: 31553254
Drug: Low-dose EGF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose EGF
Study: 31553254
Drug: High-dose EGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose EGF
Study: 31553254
Drug: Low-dose EGF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose EGF vs High-dose EGF
Study: 28059565
Drug: message reception
Approvals — FDA: no, EMA: no, PMDA: no
Description: message reception and expression (treatment group)
Study: 17690485
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of hop water extract (HWE)
Study: 15694055
Drug: Intramuscular etofenamate
Normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular etofenamate (1 g/day)
Study: 15694055
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac (75 mg/day)
Study: 2923424
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of morphine sulphate
Study: 2923424
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of ketamine hydrochloride
Study: 2923424
Drug: Combined continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined continuous subcutaneous infusion of morphine sulphate and ketamine hydrochloride
Study: 2923424
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine sulphate
Study: 31494365
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 1.0 mg/kg
Study: 31494365
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 0.5 mg/kg
Study: 31494365
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 0.1 mg/kg
Study: 22967997
Drug: Platinum throughout
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum throughout treatment
Study: 10705078
Drug: Insulin (euglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (euglycemic hyperinsulinemic clamping)
Study: 10705078
Drug: Insulin (stopped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (stopped after clamping)
Study: 29458931
Drug: Horticultural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural therapy program (10 sessions, once a week from April 2017 to June 2017)
Study: 26660337
Drug: Low-intensity wheelchair
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity wheelchair training (30-40% heart rate reserve, twice a week, for 30 min per session)
Study: 25592012
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 800 μg/d
Study: 14974365
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose of CyA and daclizumab (group A)
Study: 14974365
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose of CyA without daclizumab (group B)
Study: 9363911
Drug: Azelastine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (4 mg/day)
Study: 8489205
Drug: Lazabemide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazabemide 400 mg/day
Study: 29203092
Drug: Pemafibrate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate 0.2 mg/d
Study: 29203092
Drug: Pemafibrate 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate 0.4 mg/d
Study: 29203092
Drug: Fenofibrate 106.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 106.6 mg/d
Study: 27486235
Drug: DHEA (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (800 mg)
Study: 27486235
Drug: DHEA (1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (1,600 mg)
Study: 18272323
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic medication
Study: 15863811
Drug: Conventional antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotic medication
Study: 1291926
Drug: Nimesulide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (1 tablet b.i.d. for 10 days)
Study: 1291926
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (1 tablet b.i.d. for 10 days)
Study: 3908879
Drug: Regular exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular exercise (endurance training), thrice weekly for one year
Study: 24148608
Drug: Cardioembolic stroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioembolic stroke (patients unwilling or unable to take oral anticoagulants)
Study: 18518865
Drug: Oxygen flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen flow rate of 5 l.min(‐1)
Study: 18518865
Drug: Oxygen flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen flow rate of 10 l.min(‐1)
Study: 18518865
Drug: Oxygen flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen flow rate of 15 l.min(‐1)
Study: 12735671
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg) plus intravenous prednisolone (1 mg/kg)
Study: 12735671
Drug: Intravenous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prednisolone (1 mg/kg)
Study: 1662978
Drug: Alkalinized local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalinized local anaesthetic mixture (0.5% bupivacaine 10 ml, 2% lignocaine 10 ml with adrenaline 1 in 200,000, plus 8.4% sodium bicarbonate 2 ml)
Study: 1662978
Drug: Plain local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain local anaesthetic mixture (0.5% bupivacaine 10 ml and 2% lignocaine 10 ml with adrenaline 1 in 200,000)
Study: 6172942
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with 0.05% retinoic acid without occlusion
Study: 25285468
Drug: Caffeinated nitric
Normalized name: Nitric Acid
DrugBank: Nitric acid (DB15995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated nitric oxide lozenge (70mg)
Study: 24342530
Drug: ω‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 PUFA supplementation (EPA: 1.67 g EPA + 0.16 g DHA/d; n = 12)
Study: 24342530
Drug: ω‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 PUFA supplementation (DHA: 1.55 g DHA + 0.40 g EPA/d; n = 12)
Study: 24342530
Drug: ω‐6 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐6 PUFA linoleic acid (LA: 2.2 g/d; n = 9)
Study: 20024700
Drug: Polyalkylimide gel
Normalized name: polyacrylamide (10000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyalkylimide gel (PAIG) injections at week 0 and 6
Study: 12368394
Drug: (n-3) fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (n-3) fatty acids (1.5 g daily)
Study: 10099032
Drug: Tiagabine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (titrated from 8 to 48 mg/d)
Study: 7862924
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum and patch
Study: 2764865
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (16 two-hour sessions over 4 consecutive days)
Study: 2764865
Drug: Spaced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spaced treatment (two two-hour sessions per week for eight weeks)
Study: 2764865
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment formats
Study: 324830
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Anafranil and Pertofran
Study: 27939035
Drug: Early introduction
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early introduction of heated egg powder (50 mg/day from 6 to 9 months, 250 mg/day from 9 to 12 months)
Study: 25806626
Drug: Action Planning
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Action Planning and Coping Planning strategies for medication adherence
Study: 24112026
Drug: milatuzumab 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: milatuzumab 1.5 mg/kg, 4.0 mg/kg, 8.0 mg/kg, or 16.0 mg/kg administered twice weekly x 4
Study: 11295628
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein intervention in men with PSA failure (PSA 0.1 to 2.0 ng/mL), treatment duration of 8 months.
Study: 7981558
Drug: G‐ORS (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐ORS (standard glucose ORS)
Study: 29357333
Drug: 10 mL,
Normalized name: syringe, ENFit 10 mL, sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL, 40 µg/mL of O₃‐O₂
Study: 29357333
Drug: 10 mL,
Normalized name: syringe, ENFit 10 mL, sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL, 30 µg/mL of O₃‐O₂
Study: 20421817
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (high-dose single-drug ifosfamide)
Study: 18387719
Drug: RTS,S/AS02 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS02 vaccine on a 0, 1, and 3 month schedule